X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABNCoV2
Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
A neutralization test of samples from the study of ABNCoV2 has now confirmed similarly high levels of neutralizing antibodies against the SARS-CoV2 variants B.1.1.7 (British) and B.1.351 (South African).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABNCoV2
Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Radhoud University Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
The latest data confirm the previous strong immunogenicity results already published, and further demonstrate a protective efficacy of ABNCoV2 post-challenge with SARS-CoV-2.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
